Advanced in Virilizing Ovarian Tumor

Dr. Leslie R. Boyd

Gynecologic Oncology | Obstetrics and Gynecology
New York University
550 1st Ave, 
New York, NY 
Advanced in Virilizing Ovarian Tumor
New York University
550 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leslie Boyd is a Gynecologic Oncologist and an Obstetrics and Gynecologist in New York, New York. Dr. Boyd is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Oophorectomy, and Hysterectomy.

Her clinical research consists of co-authoring 39 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Hospital Affiliations
Nyu Langone Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

NEW YORK UNIVERSITY
550 1st Ave, New York, NY 10016
Other Locations
NEW YORK UNIVERSITY
111 Broadway, 2ndf, New York, NY 10006
NEW YORK UNIVERSITY
240 E 38th St, New York, NY 10016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Biological, Device
Study Drug: VGX-3100
Study Phase: Phase 3
Identification of Circulating Tumor Cells in Patients With HPV 16 or 18 Associated Cervical Cancer
Identification of Circulating Tumor Cells in Patients With HPV 16 or 18 Associated Cervical Cancer
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Diagnostic test
View 4 Less Clinical Trials

39 Total Publications

What are we worth? An SGO analysis of compensation structures that measure and value work in academic gynecologic oncology practices.
What are we worth? An SGO analysis of compensation structures that measure and value work in academic gynecologic oncology practices.
Journal: Gynecologic oncology
Published: April 10, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Whitfield B. Growdon
Gynecologic Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Whitfield B. Growdon
Gynecologic Oncology | Obstetrics and Gynecology

New York University

240 E 38th St, 
New York, NY 
 (0.3 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Whitfield Growdon is a Gynecologic Oncologist and an Obstetrics and Gynecologist in New York, New York. Dr. Growdon is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Oophorectomy.

Distinguished in Virilizing Ovarian Tumor
Dr. Dennis S. Chi
Gynecologic Oncology | Oncology | General Surgery
Distinguished in Virilizing Ovarian Tumor
Dr. Dennis S. Chi
Gynecologic Oncology | Oncology | General Surgery

Mskcc Surgery Group

1275 York Ave, 
New York, NY 
 (1.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dennis Chi is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Chi is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Oophorectomy, and Salpingo-Oophorectomy. Dr. Chi is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Oliver Zivanovic
Gynecologic Oncology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Oliver Zivanovic
Gynecologic Oncology | Oncology
1275 York Ave, 
New York, NY 
 (1.7 miles away)
212-639-7033
Languages Spoken:
English
See accepted insurances

Oliver Zivanovic is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Zivanovic is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Lymphadenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boyd's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile